| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.4M | — | +44.6% |
| SG&A Expense | $1.7M | — | +7.2% |
| Net Income | -$5.0M | — | -31.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.1M | -18.2% | -18.3% |
| Short-term Investments | $10.9M | -26.9% | — |
| Current Assets | $15.3M | -23.4% | +22.7% |
| Total Assets | $15.7M | -23.0% | +21.1% |
| Current Liabilities | $5.3M | -3.6% | +10.1% |
| Total Liabilities | $6.9M | -4.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.9M | — | -87.7% |
| Investing Cash Flow | $4.1M | — | +48.7% |
| Financing Cash Flow | $56K | — | +143.8% |
| -1.6% |
| Stockholders' Equity | $8.8M | -33.1% | +48.0% |